$ACHV Cashflow Statement | Understand Stock

$ACHV

$6.54 +$0.05 (0.77%) Close

$ACHV Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating Activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization [note 5]
Depreciation and amortization [note 4]
Stock-based compensation [note 10[c], note 10[d], note 10[e]] and note 10[f]]
Shares issued as settlement with trade vendor
Accrued interest on SVB convertible debt [note 8]
Amortization of 2024 SVB convertible term loan transaction costs [note 8]
Accretion of discount on modification of debt [note 8]
Loss on extinguishment of 2023 SVB convertible term loan [note 8]
Change in fair value of contingent consideration [note 4 and note 5]

Changes in operating assets and liabilities:
Grant receivable
Prepaid expenses and other assets
Nonrelated Party
Adare Pharma Solutions
Total prepaid expenses and other assets
Accounts payable
Nonrelated Party
Adare Pharma Solutions
Total accounts payable
Accrued liabilities other
Nonrelated Party
Adare Pharma Solutions
Total accrued liabilities other
Accrued clinical liabilities
Accrued compensation
Lease obligation
Net cash used in operating activities
Financing Activities:
Proceeds from exercise of warrants [note 10[g]]
Proceeds from ATM, net of issuance costs [note 11[b]]
Proceeds from employee stock purchase plan [note 10[e]]
Taxes paid related to net share settlement of equity awards
Proceeds from private placement, net of issuance costs [note 10[b]]
November 2022 Private Placement
May 2023 Private Placement
Proceeds from registered direct offering, net of issuance costs
Proceeds from June 2025 public offering, net of issuance costs [note 7b]
Proceeds from June 2025 public offering exercise of overallotment option, net of issuance costs [note 10b]
Repayment of 2023 SVB convertible term loan [note 6 and note 8]
Receipt of 2024 SVB convertible term loan less transaction costs [note 6 and note 8]
Financing costs relating to convertible debt with SVB [note 9]
Receipt of 2024 SVB convertible term loan second tranche [note 6 and note 8]
Net cash provided by financing activities

Investing Activities:
Purchase of property and equipment
Loss on disposal of property and equipment
Realized gain on investments
Purchase of investments
Maturities of investments
Net cash provided by (used in) investing activities
Effect of exchange rate changes on cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year

Comments